Compare SENEB & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SENEB | OMER |
|---|---|---|
| Founded | 1949 | 1994 |
| Country | United States | United States |
| Employees | 6895 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 772.8M |
| IPO Year | N/A | 2008 |
| Metric | SENEB | OMER |
|---|---|---|
| Price | $158.50 | $10.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 649.0 | ★ 2.0M |
| Earning Date | 06-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.62 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $233.22 |
| P/E Ratio | ★ $12.93 | $16.90 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $101.56 | $2.95 |
| 52 Week High | $178.00 | $17.65 |
| Indicator | SENEB | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 63.93 | 45.68 |
| Support Level | $132.23 | $9.54 |
| Resistance Level | $164.98 | $12.06 |
| Average True Range (ATR) | 3.04 | 0.81 |
| MACD | 1.64 | 0.14 |
| Stochastic Oscillator | 56.67 | 89.99 |
Seneca Foods Corp is a provider of packaged fruits and vegetables. The facilities are comprised of plants for packaging, can manufacturing, seed production, a farming operation and a logistical support network. The Company manages its business almost entirely on the basis of two reportable food packaging segments: Vegetable and Fruit/Snack. The Other category comprises non-food operations including revenue derived from the sale of cans, ends, seed, and outside revenue from the Company's aircraft operations, and certain corporate items. The Company's principal product offerings include canned, frozen and jarred fruits and vegetables, as well as packaged snack chips. Its brands are Aunt Nellie's, Cherry man, GREEN VALLEY, Libby's, READ, and SENECA APPLE CHIPS.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.